* D Narain, President, Bayer South Asia and Managing Director, Bayer CropScience Limited takes on an enhanced leadership role as the Global Head of Smallholder Farming
* Simon Thorsten Wiebusch, Chief Operating Officer, Crop Science Division of Bayer for India, Bangladesh & Sri Lanka appointed as Executive Director, Bayer CropScience Limited and Country Divisional Head of Crop Science Business in India, Bangladesh and Sri Lanka
Bayer, a global life sciences company present in India for over 125 years, today announced enhanced leadership roles for D Narain and Simon Thorsten Wiebusch, two senior executives from its India team to support its strong commitment to improve the livelihood of 100 million smallholders globally and deliver sustainable farming solutions.
D Narain, currently President, Bayer South Asia, and MD, Bayer CropScience Ltd takes on additional leadership responsibilities as Global Head of Smallholder Farming for Bayer.
Simon Thorsten Wiebusch, who is currently COO of Bayer’s CropScience business for India, Bangladesh, and Sri Lanka (IBSL) takes over as Executive Director, Bayer CropScience Ltd and the Country Divisional Head of the Crop Science business in these countries.
D Narain and Simon will continue to be based out of India, which is the largest small farmer market in the world and also serves as Bayer CropScience’s incubator to bring new smallholder farming innovation.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.com.